Nogapendekin Alfa Combo Earns Approval in Saudi Arabia for Metastatic NSCLC
FDA Grants Fast Track Designation to SRN-101 for recurrent high-grade glioma treatment. Topics also tackle unique molecular breakthroughs and innovative treatment methodologies.
A novel small molecule shows early activity in pretreated multiple myeloma patients, providing promising data for ongoing research.
Optimistic 2025 data highlights the quality of life outcomes in OPSCC patients treated with proton compared to photon therapy, underlining improved immune preservation and reduced long-term adverse events.
PSMA-Direct Imaging and Radioligand Therapy pave the way for advanced prostate cancer treatment, with vast potentials in staging, sequencing, and access barriers tackling.
Lastly, cutting-edge research on pancreatic NET liver metastases brings hope with the characterization of TILs, showcasing the potential of TCR-based therapies due to their remarkable antitumor activity.
